Briobacept

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBriobacept
Drug Alias NameBAFF-R protein therapeutic - Biogen Idec/GenentechBLyS neutralizing moleculeBR3 Fc - Biogen Idec/Genentech
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionB-cell activating factor receptor inhibitors
TargetsB-cell activating factor receptor
Therapy Area/IndicationsSjogren's SyndromeArthritis, RheumatoidLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen (Denmark) A/SGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen (Denmark) A/SGenentech Inc
Active IndicationsN/A
Inactive IndicationsSjogren's SyndromeArthritis, RheumatoidLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A